EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Insights into Hepatocellular Carcinoma in Patients with Thalassemia: From Pathophysiology to Novel Therapies

Pei-Chin Lin, Wan-Yi Hsu, Po-Yi Lee, Shih-Hsien Hsu iD, Shyh-Shin Chiou iD

International Journal of Molecular Sciences · 10.08.2023 · 24 (16) · 12654

DOI: 10.3390/ijms241612654 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 10.08.2023. Verfasst von Pei-Chin Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Hematology and Oncology, Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung 807378, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Thalassemia, Iron Overload. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Taiwan, Kaohsiung Medical University Hospital, Kaohsiung Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thalassemia is a heterogeneous congenital hemoglobinopathy common in the Mediterranean region, Middle East, Indian subcontinent, and Southeast Asia with increasing incidence in Northern Europe and North America due to immigration. Iron overloading is one of the major long-term complications in patients with thalassemia and can lead to organ damage and carcinogenesis. Hepatocellular carcinoma (HCC) is one of the most common malignancies in both transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT). The incidence of HCC in patients with thalassemia has increased over time, as better chelation therapy confers a sufficiently long lifespan for the development of HCC. The mechanisms of iron-overloading-associated HCC development include the increased reactive oxygen species (ROS), inflammation cytokines, dysregulated hepcidin, and ferroportin metabolism. The treatment of HCC in patients with thalassemia was basically similar to those in general population. However, due to the younger age of HCC onset in thalassemia, regular surveillance for HCC development is mandatory in TDT and NTDT. Other supplemental therapies and experiences of novel treatments for HCC in the thalassemia population were also reviewed in this article.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsThalassemiaIron OverloadHumansPatientsIron

Stichwörter der Autor:innen

hepatocellular carcinoma (HCC)ironnon-transfusion-dependent thalassemia (NTDT)reactive oxygen species (ROS)thalassemiatransfusion-dependent thalassemia (TDT)

Substanzen

Iron

Autor:innen und Institutionen

  • Division of Pediatric Hematology and Oncology, Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung 807378, Taiwan.
  • School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807378, Taiwan.
  • Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807378, Taiwan.
  • Center of Applied Genomics, Kaohsiung Medical University, Kaohsiung 807378, Taiwan.
  • Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807378, Taiwan.
  • Division of Laboratory Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807378, Taiwan.

ORCID-Profile: Shih-Hsien Hsu, Shyh-Shin Chiou

Förderung

  • Ministry of Science and Technology, Taiwan
  • Kaohsiung Medical University Hospital
  • Kaohsiung Medical University
  • Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
  • Kaohsiung Medical University, Kaohsiung, Taiwan
  • National Science and Technology Council, Taiwan

Zitieren

APA

Lin, P. C., Hsu, W. Y., Lee, P. Y., Hsu, S. H., & Chiou, S. S. (2023). Insights into Hepatocellular Carcinoma in Patients with Thalassemia: From Pathophysiology to Novel Therapies. International Journal of Molecular Sciences, 24(16), 12654. https://doi.org/10.3390/ijms241612654

Vancouver

Lin PC, Hsu WY, Lee PY, Hsu SH, Chiou SS. Insights into Hepatocellular Carcinoma in Patients with Thalassemia: From Pathophysiology to Novel Therapies. International Journal of Molecular Sciences. 2023;24(16):12654. doi:10.3390/ijms241612654

BibTeX
@article{Lin2023,
  author = {Lin, Pei-Chin and Hsu, Wan-Yi and Lee, Po-Yi and Hsu, Shih-Hsien and Chiou, Shyh-Shin},
  title = {Insights into Hepatocellular Carcinoma in Patients with Thalassemia: From Pathophysiology to Novel Therapies},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {16},
  pages = {12654},
  doi = {10.3390/ijms241612654}
}
Kostenlos starten →